Overview
Retatrutide is a next-generation triple receptor agonist, simultaneously engaging GLP-1, GIP, and glucagon receptors. This triple mechanism distinguishes it from earlier dual-agonist compounds and has positioned it as one of the most intensively studied peptides in current metabolic and endocrine research.
Nova Biolabs holds Retatrutide 10mg in UK domestic stock, HPLC-verified at >98% purity, and dispatches with fast, discreet packaging.
Key Research Areas
Triple Receptor Pharmacology
Retatrutide's simultaneous engagement of GLP-1, GIP, and glucagon receptors provides a unique research tool for studying the combined effects of incretin and glucagon signalling.
Glucagon Receptor Research
The addition of glucagon receptor agonism — absent in Tirzepatide — makes Retatrutide particularly valuable for researchers studying hepatic glucose production and energy expenditure pathways.
Comparative Agonist Studies
Frequently used alongside GLP-1-only and dual agonists to isolate the contribution of each receptor pathway in metabolic signalling models.
Energy Homeostasis Research
The triple-receptor profile has generated significant research interest in its effects on energy expenditure, thermogenesis signalling, and adipose tissue metabolism.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 10mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |